InvestorsHub Logo
Followers 15
Posts 1769
Boards Moderated 0
Alias Born 07/25/2013

Re: None

Monday, 01/11/2016 12:05:52 PM

Monday, January 11, 2016 12:05:52 PM

Post# of 2001
Added some more to lower my Avg. I like this part:

SHAPE also showed improvement in pruritus (itch), a significant symptom associated with CTCL. Thirty-eight percent of patients demonstrated a clinically meaningful decrease in pruritus during the study as measured by a Visual Analog Scale. The drug was well tolerated by patients in the study. The 60 patient study is now fully enrolled, and the company expects that final results will be available in mid-2016.